Claims
- 1. A method for treating a patient suffering from cancer, said method comprising the step of administering to the patient an effective amount of a compound selected from the group consisting of N-docosahexaenoyl-cysteamine-S-phosphate, N-eicosapentaenoyl-cysteamine-S-phosphate, N-arachidonoyl-cysteamine-S-phosphate, N-α-linolenoyl-cysteamine-S-phosphate, and N-γ-linolenoyl-cysteamine-S-phosphate.
- 2. A method for treating a patient suffering from cancer, said method comprising the step of administering to the patient an effective amount of a compound selected from the group consisting of N-docosahexaenoyl-cysteamine-S-phosphate, N-eicosapentaenoyl-cysteamine-S-phosphate, N-arachidonoyl-cysteamine-S-phosphate, N-α-linolenoyl-cysteamine-S-phosphate, and N-γ-linolenoyl-cysteamine-S-phosphate in admixture or simultaneously with N-(all-trans-retinoyl)-O-phospho-L-tyrosine.
- 3. A method for treating a patient suffering from cancer, said method comprising the step of administering to the patient an effective amount of a compound selected from the group consisting of N-docosahexaenoyl-cysteamine-S-phosphate, N-eicosapentaenoyl-cysteamine-S-phosphate, N-arachidonoyl-cysteamine-S-phosphate, N-α-linolenoyl-cysteamine-S-phosphate, and N-γ-linolenoyl-cysteamine-S-phosphate in admixture or simultaneously with N-(13-cis-retinoyl)-O-phospho-L-tyrosine.
- 4. A substantially pure compound selected from the group consisting of N-docosahexaenoyl-cysteamine-S-phosphate, N-eicosapentaenoyl-cysteamine-S-phosphate, N-arachidonoyl-cysteamine-S-phosphate, N-α-linolenoyl-cysteamine-S-phosphate, and N-γ-linolenoyl-cysteamine-S-phosphate.
- 5. A pharmaceutical preparation, characterized in that it comprises a therapeutically effective amount of a compound according to claim 1.
- 6. A pharmaceutical preparation, characterized in that it comprises a therapeutically effective amount of a compound according to claim 1 in micellar form.
- 7. A pharmaceutical preparation, characterized in that it comprises a therapeutically effective amount of a compound selected from the group consisting of N-docosahexaenoyl-O-phospho-2-aminoethanol, N— eicosapentaenoyl O-phospho-2-aminoethanol, N-arachidonoyl O-phospho-2-aminoethanol, N-α-linolenoyl O-phospho-2-aminoethanol, and N-γ-linolenoyl O-phospho-2-aminoethanol.
- 8. A pharmaceutical preparation according to claim 4, characterized in that it comprises the therapeutically effective amount of the selected compound in micellar form.
- 9. A pharmaceutical preparation, characterized in that it comprises a therapeutically effective amount of a compound according to claim 1 in combination with a therapeutically effective amount of N-(all-trans-retinoyl)-O-phospho-L-tyrosine.
- 10. A pharmaceutical preparation, characterized in that it comprises a therapeutically effective amount of a compound according to claim 1 in combination with a therapeutically effective amount of N-(13-cis-retinoyl)-O-phospho-L-tyrosine.
- 11. A pharmaceutical preparation, characterized in that it comprises a therapeutically effective amount of a compound selected from the group consisting of N-docosahexaenoyl-O-phospho-2-aminoethanol, N-eicosapentaenoyl O-phospho-2-aminoethanol, N-arachidonoyl O-phospho-2-aminoethanol, N-α-linolenoyl O-phospho-2-aminoethanol, and N-γ-linolenoyl O-phospho-2-aminoethanol in combination with a therapeutically effective amount of N-(all-trans-retinoyl)-O-phospho-L-tyrosine.
- 12. A pharmaceutical preparation, characterized in that it comprises a therapeutically effective amount of a compound selected from the group consisting of N-docosahexaenoyl-O-phospho-2-aminoethanol, N-eicosapentaenoyl O-phospho-2-aminoethanol, N-arachidonoyl O-phospho-2-aminoethanol, N-α-linolenoyl O-phospho-2-aminoethanol, and N-γ-linolenoyl O-phospho-2-aminoethanol in combination with a therapeutically effective amount of N-(13-cis-retinoyl)-O-phospho-L-tyrosine.
- 13. A pharmaceutical preparation, characterized in that it comprises a therapeutically effective amount of N-docosahexaenoyl-cysteamine-S-phosphate and one of N-(all-trans-retinoyl)-O-phospho-L-tyrosine or N-(13-cis-retinoyl)-O-phospho-L-tyrosine.
- 14. A pharmaceutical preparation, characterized in that it comprises a therapeutically effective amount of N-eicosapentaenoyl-cysteamine-S-phosphate and one of N-(all-trans-retinoyl)-O-phospho-L-tyrosine or N-(13-cis-retinoyl)-O-phospho-L-tyrosine.
- 15. A pharmaceutical preparation, characterized in that it comprises a therapeutically effective amount of N-arachidonoyl-cysteamine-S-phosphate and one of N-(all-trans-retinoyl)-O-phospho-L-tyrosine or N-(13-cis-retinoyl)-O-phospho-L-tyrosine.
- 16. A pharmaceutical preparation, characterized in that it comprises a therapeutically effective amount of N-α-linolenoyl-cysteamine-S-phosphate and one of N-(all-trans-retinoyl)-O-phospho-L-tyrosine or N-(13-cis-retinoyl)-O-phospho-L-tyrosine.
- 17. A pharmaceutical preparation, characterized in that it comprises a therapeutically effective amount of N-γ-linolenoyl-cysteamine-S-phosphate and one of N-(all-trans-retinoyl)-O-phospho-L-tyrosine or N-(13-cis-retinoyl)-O-phospho-L-tyrosine.
- 18. Use of a compound according to claim 1 for the manufacture of a pharmaceutical preparation.
- 19. Use of a compound according to claim 1 for the manufacture of a pharmaceutical preparation for the treatment of cancer.
- 20. Use of a compound for the manufacture of a pharmaceutical preparation, said compound being selected from the group consisting of N-docosahexaenoyl-O-phospho-2-aminoethanol, N-eicosapentaenoyl O-phospho-2-aminoethanol, N-arachidonoyl O-phospho-2-aminoethanol, N-α-linolenoyl O-phospho-2-aminoethanol, and N-γ-linolenoyl O-phospho-2-aminoethanol.
- 21. Use of a compound for the manufacture of a pharmaceutical preparation for the treatment of cancer, said compound being selected from the group consisting of N-docosahexaenoyl-O-phospho-2-aminoethanol, N— eicosapentaenoyl O-phospho-2-aminoethanol, N-arachidonoyl O-phospho-2-aminoethanol, N-α-linolenoyl O-phospho-2-aminoethanol, and N-γ-linolenoyl O-phospho-2-aminoethanol.
- 22. A method for treating a patient suffering from cancer, said method comprising the step of administering to the patient an effective amount of a compound according to claim 7, in admixture with or substantially simultaneously with a cytotoxic agent.
- 23. A method for treating a patient suffering from cancer, said method comprising the step of administering to the patient an effective amount of a compound according to claim 11, in admixture with or substantially simultaneously with a cytotoxic agent.
- 24. A method for treating a patient suffering from cancer, said method comprising the step of administering to the patient an effective amount of a compound according to claim 8, in admixture with or substantially simultaneously with a cytotoxic agent.
- 25. A method for treating a patient suffering from cancer, said method comprising the step of administering to the patient an effective amount of a compound according to claim 12, in admixture with or substantially simultaneously with a cytotoxic agent.
- 26. The method of claim 22 wherein said cytotoxic agent is doxorubicin.
- 27. The method of claim 23 wherein said cytotoxic agent is doxorubicin.
- 28. The method of claim 24 wherein said cytotoxic agent is doxorubicin.
- 29. The method of claim 25 wherein said cytotoxic agent is doxorubicin.
Priority Claims (1)
Number |
Date |
Country |
Kind |
0002629 |
Jul 2000 |
SE |
|
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a U.S. National Phase application of International PCT/SE01/01559, filed Jul. 5, 2001, which claims priority to Swedish Patent Application Serial No. SE 0002629-4 filed on Jul. 12, 2000 and U.S. Provisional Application Ser. No. 60/217,810 filed on Jul. 12, 2000, all of which are hereby incorporated by reference in their entirety.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/SE01/01559 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO02/04467 |
1/17/2002 |
WO |
A |
Foreign Referenced Citations (3)
Number |
Date |
Country |
WO 9965936 |
Dec 1999 |
WO |
WO 0042832 |
Jul 2000 |
WO |
WO 0047589 |
Aug 2000 |
WO |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/217810 |
Jul 2000 |
US |